For the quarter ending 2025-09-30, ALT made $5K in revenue. -$18,991K in net income. Net profit margin of -379820.00%.
| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 5 | 5 | 5 | 5 |
| Research and development | 14,960 | 15,827 | 20,808 | 19,803 |
| General and administrative | 5,904 | 5,993 | 5,332 | 4,969 |
| Total operating expenses | 20,864 | 21,820 | 26,140 | 24,772 |
| Loss from operations | -20,859 | -21,815 | -26,135 | -24,767 |
| Interest expense | 495 | 1 | 1 | 6 |
| Interest income | 2,426 | 1,545 | 2,055 | 1,910 |
| Other income (expense), net | -86 | 15 | 10 | 18 |
| Total other income (expense), net | 1,845 | 1,559 | 2,064 | 1,922 |
| Net loss before income taxes | -19,014 | -20,256 | - | - |
| Income tax expense (benefit) | - | -681 | - | - |
| Net loss | -19,014 | -19,575 | -24,071 | -22,845 |
| Other comprehensive income - unrealized gain (loss) on short-term investments | 23 | -30 | -105 | 347 |
| Comprehensive loss | -18,991 | -19,605 | -24,177 | -22,498 |
| Net loss per share, basic | -0.21 | -0.26 | -0.34 | -0.32 |
| Net loss per share, diluted | -0.21 | -0.26 | -0.34 | -0.32 |
| Weighted average number of share outstanding basic and diluted | 89,418,028 | 75,547,746 | -27,129.333 | 71,084,787 |
| Weighted average number of shares outstanding, diluted | 89,418,028 | 75,547,746 | -27,129.333 | 71,084,787 |
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)